Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes

Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”